Basecamp Research has raised $140 million in an oversubscribed Series C financing to train a new generation of its EDEN biological foundation models and advance a pipeline of AI-designed therapeutics toward clinical development. The round was led by S32, with participation from NVIDIA, Menlo Ventures’ Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures.
Additional investment came from senior leaders across the pharmaceutical, biotechnology, and broader global industry sectors, including André Hoffmann, Vice-Chairman of Roche.
Basecamp Research is developing AI-designed medicines with the goal of creating therapies that reprogram the body to repair itself. Its platform combines frontier AI models trained on proprietary biological data with technologies for writing DNA sequences into cells.
The new funding will support development of Basecamp’s EDEN models and move its therapeutic pipeline closer to clinical development. The company plans to begin with in vivo cell therapy while also expanding its pharmaceutical partnerships.
Basecamp is applying EDEN to in vivo cell therapy, an approach designed to reprogram a patient’s cells directly inside the body. Current cell therapies can involve complex manufacturing processes and, according to the company, can cost hundreds of thousands of dollars per patient.
Basecamp’s approach pairs EDEN’s ability to design long and complex DNA sequences with large serine recombinases capable of precisely integrating those sequences into the genome. The company believes the combination could enable more sophisticated and customizable cell therapies while simplifying how treatments are administered.
Potential disease areas for the platform include cancer and autoimmune conditions, although the company’s programs remain in development.
Basecamp said it has demonstrated strong preclinical results across multiple therapeutic modalities and disease areas. The company did not provide detailed clinical data in the announcement, and its pipeline is advancing toward clinical development rather than currently being in human trials.
To support the expansion of its relationships with pharmaceutical companies, Basecamp has appointed Richard Pearce as Chief Business Officer. Pearce previously worked at Biogen.
S32 General Partner Andy Conrad, the former CEO of Google’s Verily, is also joining Basecamp Research’s board of directors as part of the financing.
At the center of Basecamp’s technology platform is the Trillion Gene Atlas, which the company describes as the world’s largest proprietary biological AI training dataset.
The dataset was built with partners including NVIDIA, Anthropic, PacBio, and Ultima Genomics. It incorporates biological data collected through access and benefit-sharing partnerships spanning more than 30 countries across all seven continents.
Basecamp uses the dataset to train its EDEN biological foundation models. Rather than developing separate AI systems for individual scientific tasks, the company is building EDEN to identify patterns across a broad range of biological information and develop a more general understanding of how DNA functions across different forms of life.
The company said this approach allows its models to generate potential therapeutic candidates directly from information about a disease.
Basecamp has already demonstrated aspects of this capability through its collaboration with Anthropic on Claude Science. The EDEN platform is designed to support applications including cell therapies, gene therapies, enzymes, and peptides.
The Series C financing provides Basecamp with additional capital to expand the models, advance internally developed therapies, and pursue additional partnerships with pharmaceutical and biotechnology companies.
The round also adds several strategic and institutional investors to Basecamp’s shareholder base, including NVIDIA and the NATO Innovation Fund, alongside existing and new venture, philanthropic, and technology-focused backers.
Basecamp was founded in 2024 and is headquartered in London, with additional offices and laboratory operations in Cambridge, Massachusetts.
The company is positioning its combination of proprietary biological datasets, foundation models, and DNA design technologies as an integrated platform for therapeutic discovery and development.
Its initial internal focus on in vivo cell therapy represents one application of the broader EDEN platform. Longer term, Basecamp intends to apply its technology across additional therapeutic modalities while using its biological datasets and AI models to support collaborations with external drug developers.
KEY QUOTES:
“We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how. AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most.”
Glen Gowers, Co-Founder And CEO Of Basecamp Research
“The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey. Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate.”
André Hoffmann, Vice-Chairman Of Roche
“AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people’s lives. Basecamp Research is building an important technology platform at the center of that opportunity.”
Andy Conrad, General Partner At S32
